Health
New head lice treatment approved for use in USA – Mirage News
L – R Hatchtech CEO Hugh Alsop, Associate Professor Vern Bowles and Hatchtech Chairman Paul Kelly. Photo: supplied. A new prescription head lice…
L – R Hatchtech CEO Hugh Alsop, Associate Professor Vern Bowles and Hatchtech Chairman Paul Kelly. Photo: supplied.
A new prescription head lice treatment, developed by University of Melbourne Associate Professor Vern Bowles, has been given Food and Drug Administration (FDA) approval, allowing it to be sold in the USA.
The treatment, Xeglyze™, was developed by Hatchtech, an Australian pharmaceutical company and will be commercialised by Dr Reddy’s Laboratories.
Hatchtech CEO Hugh Alsop estim…
-
Business22 hours agoWhy Auckland Airport, Australian Ethical, Breville, and Clarity shares are charging higher
-
Business23 hours agoMacquarie increases price target for Qantas shares
-
Noosa News22 hours agoCommonwealth Bank executive Christopher James McCann found dead in Springbrook National Park
-
Noosa News24 hours agoHoyts Is Set to Launch Up to Five New IMAX Screens in Australia — Including at Melbourne Central Before the End of 2025